QIAGEN has acquired Amnisure, a privately-owned Boston, MA-based company that markets the Amnisure assay for determining whether a pregnant woman is suffering rupture of foetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely.
Although financial terms of the agreement to acquire Amnisure were not disclosed, QIAGEN expects this acquisition to be neutral to adjusted diluted EPS in 2012, but to be enhancing to enhancings by 2013. The acquisition is expected to contribute approximately US$12 million to QIAGEN for the remainder of 2012 and full-year sales of approximately US$24 million in 2013. QIAGEN expects to incur one-time charges and integration costs of approximately US$5 million in 2012, which primarily relate to restructuring efforts and integration activities in connection with the transaction.
Around 30 per cent of pregnant women are checked in clinical settings for ROM, a widespread cause of premature delivery and complications requiring admission to neonatal intensive care units. Amnisure is a point-of-need test that provides reliable results in an emergency room, birthing centre or clinic. Obstetricians and gynaecologists, who are the primary prescribers of Amnisure in pregnancy, also routinely screen patients for human papillomavirus (HPV) as part of cervical cancer prevention testing.
QIAGEN expects the growth impulses from offering this product to boost its small, but growing, point-of-care portfolio, which is led by the QIAGEN ESE quant lateral flow readers and tube scanners, to serve the growing worldwide demand for point-of-need diagnostics. The Amnisure ROM test is cleared by the FDA for marketing and is reimbursable under most US state Medicaid plans, and is also approved in other markets around the world.